Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity

Human Molecular Genetics

Volumn 13, Issue 2, 2004, Pages 151-157

  Ohsawa, Yutaka ^a   Toko, Haruhiro ^b   Katsura, Masashi ^a   Morimoto, Kazue ^a   Yamada, Haruki ^a   Ichikawa, Yaeko ^a   Murakami, Tatsufumi ^a   Ohkuma, Seitaro ^a   Komuro, Issei ^b   Sunada, Yoshihide ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 3; ISOENZYME; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BIOCHEMISTRY; CARDIOVASCULAR PARAMETERS; CAVEOLA; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE LOSS; GENE OVEREXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HYPERTROPHIC CARDIOMYOPATHY; IN VIVO STUDY; KNOCKOUT MOUSE; LIMB GIRDLE MUSCULAR DYSTROPHY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SARCOLEMMA; TRANSGENIC MOUSE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CAVEOLIN 3; CAVEOLINS; CYTOPLASM; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III;

ANIMALIA; MUS MUSCULUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 1342268582     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddh014     Document Type: Article

References (35)

1. Razani, B., Schlegel, A. and Lisanti, M.P. (2000) Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy. J. Cell Sci., 113, 2103-2109.
2. Monier, S., Parton, R.G., Vogel, F., Behlke, J., Henske, A. and Kurzchalia, T.V. (1995) VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol. Biol. Cell, 6, 911-927.
3. Couet, J., Li, S., Okamoto, T., Ikezu, T. and Lisanti, M.P. (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem., 272, 6525-6533.
4. Galbiati, F., Razani, B. and Lisanti, M.P. (2001) Emerging themes in lipid rafts and caveolae. Cell, 106, 403-411.
5. Feron, O., Belhassen, L., Kobzik, L., Smith, T.W., Kelly, R.A. and Michel, T. (1996) Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem., 271, 22810-22814.
6. Kobzik, L., Reid, M.B., Bredt, D.S. and Stamler, J.S. (1994) Nitric oxide in skeletal muscle. Nature, 372, 546-548.
7. Venema, V.J., Ju, H., Zou, R. and Venema, R.C. (1997) Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J. Biol. Chem., 272, 28187-28190.
8. Garcia-Cardena, G., Martasek, P., Masters, B.S., Skidd, P.M., Couet, J., Li, S., Lisanti, M.P. and Sessa, W.C. (1997) Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem., 272, 25437-25440.
9. Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E., Mazzocco, M., Egeo, A., Donati, M.A. et al. (1998) Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet., 18, 365-368.
10. Betz, R.C., Schoser, B.G., Kasper, D., Ricker, K., Ramirez, A., Stein, V., Torbergsen, T., Lee, Y.A., Nothen, M.M., Wienker, T.F. et al. (2001) Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat. Genet., 28, 218-219.
11. Sunada, Y., Ohi, H., Hase, A., Ohi, H., Hosono, T., Arata, S., Higuchi, S., Matsumura, K. and Shimizu, T. (2001) Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum. Mol. Genet., 10, 173-178.
12. Fujita, T., Toya, Y., Iwatsubo, K., Onda, T., Kimura, K., Umemura, S. and Ishikawa, Y. (2001) Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc. Res., 51, 709-716.
13. Winlaw, D.S., Smythe, G.A., Keogh, A.M., Schyvens, C.G., Spratt, P.M. and Macdonald, P.S. (1994) Increased nitric oxide production in heart failure. Lancet, 344, 373-374.
14. Stein, B., Eschenhagen, T., Rudiger, J., Scholz, H., Forstermann, U. and Gath, I. (1998) Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J. Am. Coll. Cardiol., 32, 1179-1186.
15. Barouch, L.A., Harrison, R.W., Skaf, M.W., Rosas, G.O., Cappola, T.P., Kobeissi, Z.A., Hobai, I.A., Lemmon, C.A., Burnett, A.L., O'Rourke, B. et al. (2002) Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature, 416, 337-341.
16. Balligand, J.L., Kelly, R.A., Marsden, P.A., Smith, T.W. and Michel, T. (1993) Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl Acad. Sci. USA, 90, 347-351.
17. G-methyl-L-arginine decreases contractility, cGMP and cAMP in isoproterenol-stimulated rat hearts in vitro. Eur. J. Pharmac., 223, 1-7.
18. Balligand, J.L., Kobzik, L., Han, X., Kaye, D.M., Belhassen, L., O'Hara, D.S., Kelly, R.A., Smith, T.W. and Michel, T. (1995) Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J. Biol. Chem., 270, 14582-14586.
19. Hare, J.M., Lofthouse, R.A., Juang, G.J., Colman, L., Ricker, K.M., Kim, B., Senzaki, H., Cao, S., Tunin, R.S. and Kass, D.A. (2000) Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Circul. Res., 86, 1085-1092.
20. Hare, J.M., Givertz, M.M., Creager, M.A. and Colucci, W.S. (1998) Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of β-adrenergic inotropic responsiveness. Circulation, 97, 161-166.
21. 2+ release in cardiomyocytes. Nat. Cell. Biol., 3, 867-873.
22. Xu, K.Y., Huso, D.L., Dawson, T.M., Bredt, D.S. and Becker, L.C. (1999) Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc. Natl Acad. Sci. USA, 96, 657-662.
23. Xu, L., Eu, J.P., Meissner, G. and Stamler, J.S. (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science, 279, 234-237.
24. Brunner, F., Andrew, P., Wolkart, G., Zechner, R. and Mayer, B. (2001) Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation, 104, 3097-3102.
25. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J. Biol. Chem., 268, 26286-26295.
26. Vila-Petroff, M.G., Younes, A., Egan, J., Lakatta, E.G. and Sollott, S.J. (1999) Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circul. Res., 84, 1020-1031.
27. 2+ in intact cardiac myocytes. Circul. Res., 74, 970-978.
28. Woodman, S.E., Park, D.S., Cohen, A.W., Cheung, M.W., Chandra, M., Shirani, J., Tang, B., Jelicks, L.A., Kitsis, R.N., Christ, G.J. et al. (2002) Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J. Biol. Chem., 277, 38988-38997.
29. Ricker, K., Moxley, R.T. and Rohkamm, R. (1989) Rippling muscle disease. Arch. Neurol., 46, 405-408.
30. Toko, H., Oka, T., Zou, Y., Sakamoto, M., Mizukami, M., Sano, M., Yamamoto, R., Sugaya, T. and Komuro, I. (2002) Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res., 25, 597-603.
31. Bredt, D.S. and Snyder, S.H. (1990) Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl Acad. Sci. USA, 87, 682-685.
32. 2+-independent nitric oxide synthase in the myocardium. Br. J. Pharmac., 105, 575-580.
33. Bia, B.L., Cassidy, P.J., Young, M.E., Rafael, J.A., Leighton, B., Davies, K.E., Radda, G.K. and Clark, K. (1999) Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J. Mol. Cell. Cardiol., 31, 1857-1862.
34. w-propyl-L-arginine. J. Med. Chem., 40, 3869-3870.
35. Kakoki, M., Zou, A.-P. and Mattson., D.L. (2001) The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol., 281, R91-R97.